HDAC9 and lung adenocarcinoma: Furthermore, treatment of lung adenocarcinoma cells with broad-spectrum HDAC and Class I HDAC-specific inhibitors alone or in combination with an EGFR inhibitor induces anti-tumor effects, including apoptosis and a reduction in cell migration, angiogenesis, and proliferation, as well as re-sensitization of cells that were resistant to chemotherapy drugs or EGFR inhibition18,48,49,68.